Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VERV
- Price
- 3.26
- Stock movement up
- +0.21 (6.89%)
- Company name
- Verve Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 276.00M
- Ent value
- 272.65M
- Price/Sales
- 11.31
- Price/Book
- 0.54
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -59.30%
- 3 year return
- -45.64%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VERV does not pay dividends or no data was received
Verve received FDA IND clearance for VERVE-102 to treat HeFH, adding new trial sites in the United States. Read more about VERV stock here.
March 25, 2025
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 11.31 |
| Price to Book | 0.54 |
| EV to Sales | 11.18 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 84.66M |
| EPS (TTM) | -2.33 |
| FCF per share (TTM) | -1.91 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 24.40M |
| Gross profit (TTM) | 17.83M |
| Operating income (TTM) | -226.54M |
| Net income (TTM) | -197.03M |
| EPS (TTM) | -2.33 |
| EPS (1y forward) | -2.92 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 73.07% |
| Operating margin (TTM) | -928.60% |
| Profit margin (TTM) | -807.62% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 158.71M |
| Net receivables | 2.63M |
| Total current assets | 556.46M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 663.91M |
| Accounts payable | 4.64M |
| Short/Current long term debt | 71.25M |
| Total current liabilities | 42.64M |
| Total liabilities | 155.35M |
| Shareholder's equity | 508.55M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -157.53M |
| Capital expenditures (TTM) | 4.53M |
| Free cash flow (TTM) | -162.06M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -38.74% |
| Return on Assets | -29.68% |
| Return on Invested Capital | -37.22% |
| Cash Return on Invested Capital | -30.62% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.29 |
| Daily high | 3.31 |
| Daily low | 3.04 |
| Daily Volume | 2.38M |
| All-time high | 73.99 |
| 1y analyst estimate | 26.20 |
| Beta | 1.76 |
| EPS (TTM) | -2.33 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| VERV | S&P500 | |
| Current price drop from All-time high | -95.59% | -12.89% |
| Highest price drop | -95.99% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -71.35% | -11.07% |
| Avg time to new high | 74 days | 12 days |
| Max time to new high | 901 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
276.00M
Marketcap category
Small-cap
Description
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Employees
255
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page